Adding the selective oestrogen-receptor downregulator fulvestrant to the aromatase inhibitor anastrozole in the first-line setting significantly extends long-term progression-free survival (PFS) and overall survival (OS) compared with anastrozole alone in postmenopausal women with hormone-receptor (HR)-positive metastatic breast cancer, according to the final results of the S0226 trial.
A wearable tracker, combined with action-planning, successfully improves moderate-to-vigorous physical activity (MVPA) levels in survivors of colorectal and endometrial cancers, according to a new study.
A contraceptive vaginal system (Annovera) releasing a combination of segesterone acetate and ethinyl estradiol (SA/EE) effectively inhibits ovulation up to a year even at low systemic levels of SA, reports a review study presented at ENDO 2019.
Greater parity, early age at menarche, or oral contraceptive use may increase a woman’s risk of undergoing total knee replacement (TKR) for severe knee osteoarthritis (OA), according to findings from the Singapore Chinese Health Study (SCHS).
Ovarian function in transgender men remained well-preserved even after a year of testosterone treatment, providing hope for trans men who would like to bear children in the future, according to data presented at ENDO 2019.
Sperm appears to play a role in repeat miscarriages, as elevated levels of semen reactive oxygen species (ROS), elevated sperm DNA fragmentation, and a lower percentage of normal morphology were found in male partners of women with idiopathic recurrent pregnancy loss* (RPL), according to data presented at ENDO 2019.
Using levothyroxine to treat women who were TPOAb*-positive but with normal thyroid function does not increase the rate of live birth at ≥34 weeks of gestation, according to the TABLET** study presented at ENDO 2019.